Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders having a high influence on social interactions. The number of approved treatments and clinical trials for ADHD have increased markedly during the recent decade. This analytical review provides a quantitative overview of the existing pharmacological and non-pharmacological methods of ADHD treatments investigated in clinical trials during 1999–2021. A total of 695 interventional trials were manually assessed from clinicaltrial.gov with the search term « ADHD», and trial data has been used for analysis. A clear majority of the studies investigated non-pharmacological therapies (∼80%), including many behavioral options, such as social skills training, sleep and physical activity interventions, meditation and hypnotherapy. Devices, complementary and other alternative methods of ADHD treatment are also gaining attention. The pharmacological group accounts for ∼20% of all the studies. The most common drug classes include central nervous system stimulants (e.g., methylphenidate hydrochloride, lisdexamfetamine dimesylate, amphetamine sulfate, mixed amphetamine salts, a combination of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride), selective noradrenaline reuptake inhibitors (atomoxetine, viloxazine), and alpha2 adrenergic receptor agonists (guanfacine hydrochloride, clonidine hydrochloride). Several studies investigated antidepressants (e.g., bupropion hydrochloride, vortioxetine), and atypical antipsychotics (e.g., quetiapine, aripiprazole) but these are yet not approved by the FDA for ADHD treatment. We discuss the quantitative trends in clinical trials and provide an overview of the new drug agents and non-pharmacological therapies, drug targets, and novel treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627 · cited 1×
“Many of these neurotransmitters mediate their effects through G-protein coupled receptors (GPCRs) (Lagerstrom and Schioth, 2008; Hauser et al., 2017) and are transported by corresponding”
BackgroundSelf-citationCortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,716
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Self-citationBrunoni, A. R., Nitsche, M. A., Bolognini, N., Bikson, M., Wagner, T., Merabet, L., Edwards, D. J., Valero-Cabre, A., Rotenberg, A., Pascual-Leone, A., et al. (2012) · Brain stimulation · doi:10.1016/j.brs.2011.03.002 · Cited by 1,445 · cited 1×
“It is a non-invasive, painless method of treatment that uses direct electrical currents to stimulate specific parts of the brain (Brunoni et al., 2012).”
MethodSonuga-Barke, E. J. S., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., Stevenson, J., Danckaerts, M., van der Oord, S., Döpfner, M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12070991 · Cited by 1,167 · cited 3×
“For other types of therapies evidence of efficacy from blinded assessments was needed (Sonuga-Barke et al., 2013).”
BackgroundMethodAttention deficit hyperactivity disorder
Thapar, A., & Cooper, M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00238-x · Cited by 1,043
Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., & Rudan, I. (2021) · Journal of Global Health · doi:10.7189/jogh.11.04009 · Cited by 896 · cited 1×
“The disorder affects around 5% of children and adolescents (Song et al., 2021) and 2.”
BackgroundExercise and Children’s Intelligence, Cognition, and Academic Achievement
Tomporowski, P. D., Davis, C. L., Miller, P. H., & Naglieri, J. A. (2008) · Educational Psychology Review · doi:10.1007/s10648-007-9057-0 · Cited by 874 · cited 1×
“to improvements in executive functions (Tomporowski et al., 2008; Wigal et al., 2013).”
Research works printed but not linked: 4
- APA (2013). Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA, USA: American Psychiatric Publishing.
- PDC-1421 - AdisInsight (2022). AdisInsight.springer.com. Available at: https://adisinsight.springer.com/drugs/800037456 (Accessed on October 23, 2022).
- Vallon Pharmaceuticals Inc (2021). Press release Announcement. Available at: https://www.vallon-pharma.com/news/vallon-pharmaceuticals-continues-advancement-of-pivotal-study-in-lead-development-program-adair-toward-potential-approval/ (accessed on August 26, 2021).
- Vallon Pharmaceuticals Inc (2022). Press release Announcement. Available at: https://www.vallon-pharma.com/news/vallon-pharmaceuticals-reports-additional-pharmacokinetic-and-pharmacodynamic-data-from-seal-study-of-adair/ (accessed on October 23, 2022).
Cited by
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Clark, A., Tate, B., Urban, B., Schroeder, R., Gennuso, S. A., Ahmadzadeh, S., McGregor, D., Girma, B., Shekoohi, S., & Kaye, A. D. (2023) · Health Psychology Research · doi:10.52965/001c.81043 · Cited by 52
Aldakhil, A. F. (2024) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2024.104858 · Cited by 37
Nose to Brain Delivery of Transferrin conjugated PLGA nanoparticles for clonidine
Sharma, S., Tyagi, A. K., & Dang, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126471 · Cited by 36
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228148 · Cited by 32
Self-citationLee, H., Lee, S., Hwang, M., & Woo, K. (2025) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-025-02788-5 · Cited by 31
Scekic‐Zahirovic, J., Benetton, C., Brunet, A., Ye, X., Logunov, E., Douchamps, V., Megat, S., Andry, V., Kan, V. W. Y., Stuart‐Lopez, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3665 · Cited by 28
“…for attention deficit disorder, narcolepsy, and excessive sleepiness, such as amphetamines, atomoxetine, methylphenidate, or solriamfetol ( 73 ); or anxiety and depression, such as serotonin and NA reuptake inhibitors, antagonists of inhibitory presynaptic serotonin, and NA receptors, or…”
BackgroundThe Impact of Oxidative Stress on the Epigenetics of Fetal Alcohol Spectrum Disorders
Terracina, S. A., Tarani, L., Ceccanti, M., Vitali, M., Francati, S., Lucarelli, M., Venditti, S., Verdone, L., Ferraguti, G., & Fiore, M. (2024) · Antioxidants · doi:10.3390/antiox13040410 · Cited by 34
“However, the effectiveness of medications such as stimulants for ADHD symptoms in individuals with FASD may vary due to the unique sensitivity of their alcohol-damaged brains [93,94].”
BackgroundYegencik, B., Bell, B. T., & Deniz, E. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1611145 · Cited by 32
Jackson, E. F., Riley, T. B., & Overton, P. G. (2025) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-025-09610-y · Cited by 24
“…and noradrenaline via blockade of the noradrenaline receptor, and elevates 5-HT levels in a mechanism not currently understood, highlighting the need for more preclinical investigation as to the mechanism of action of ADHD medications, particularly with regards to how 5-HT is involved [73, 74].”
Babu, A., & Joseph, A. P. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1591504 · Cited by 17
Zhang, Y., Liao, W., Rao, Y., Gao, W., & Yang, R. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.022 · Cited by 17
An intricate relationship between circadian rhythm dysfunction and psychiatric diseases
Samanta, S., & Bagchi, D. (2024) · Exploration of neuroscience · doi:10.37349/en.2024.00053 · Cited by 16
Poddar, A., Gaddam, S., Sonnaila, S., Bhavaraju, V. S. M., & Agrawal, S. (2025) · NeuroSci · doi:10.3390/neurosci6020041 · Cited by 18
“…and amphetamines, remain the most prescribed treatments [31], but alternative emerging therapies, such as cognitive behavioral therapy (CBT), behavioral interventions, emerging digital therapeutics, and the gut–brain axis, are gaining traction as complementary or standalone options [32].”
InfluentialNew frontiers in pharmacological treatment of attention-deficit hyperactivity disorder
Noah, A. A., & Sedky, H. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04328-z · Cited by 14
“These devices indicate a promising trend towards drug-free alternatives in ADHD treatment (Nazarova et al. 2022).”
Gonda, X., Bálint, S., Réthelyi, J., & Döme, P. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.03.002 · Cited by 14
Ghaderi, A., Taghizadeh, S., & Nazari, M. A. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.107755 · Cited by 13
Mao, F., Liu, Z., Fang, Q., & Liu, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07607-4 · Cited by 14
“Games often require players to hold task-relevant information (e.g., sequences, spatial locations, or rules) in mind while simultaneously manipulating new information, which aligns with the cognitive processes underlying working memory [47].”
Skalidou, S., Anestis, A., Bakolas, N. K. M., Tsoulfa, G., & Papadimitriou, K. (2023) · Healthcare · doi:10.3390/healthcare11141999 · Cited by 13
Faraone, S. V., Ward, C. L., Boucher, M., Elbekai, R. H., & Brunner, E. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2552324 · Cited by 10
“While current neurobiological perspectives on ADHD primarily emphasize dopamine and norepinephrine – key pathways involved in the action of ADHD medications [9,13,151,152]—this review aimed to broaden the scope by exploring the evidence for the involvement of serotonin in the neurobiology of ADHD.”
Olia, J. B. H., Raman, A., Hsu, C., Alkhayyat, A., & Nourazarian, A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109984 · Cited by 10
González-Devesa, D., Sánchez-Lastra, M. A., Outeda-Monteagudo, B., Diz-Gómez, J. C., & Ayán, C. (2025) · Children · doi:10.3390/children12020119 · Cited by 10
“Consequently, these limitations weaken the overall robustness and generalizability of the findings.”
Nasrallah, M., Moghrabi, A. E., Kayal, M., Matar, D., Alwan, I. H., & Fakhoury, M. (2025) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2025.2456800 · Cited by 11
Chen, X., Wang, Y., Tang, C., Chen, H., Cui, L., Yu, X., & Wang, F. (2025) · Acta Psychologica · doi:10.1016/j.actpsy.2025.105068 · Cited by 17
Karimi, M., Ghasemzadeh, S., & Fami, F. S. (2025) · Journal of Attention Disorders · doi:10.1177/10870547251387006 · Cited by 7
Shaikh, M. F., Higley, C., Campanile, C., Francis, R. L., Panja, E., Santacaterina, S., Pratesi, G., & Piaggio, D. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1672718 · Cited by 7
Young, J. L., Powell, R. N., Powell, A., Welling, L. L. M., Granata, L. E., Saal, J., & Nash, M. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06446-z · Cited by 8
“Some patients experience anxiety as a side effect of ADHD medications, and anxiety is one of the most common complications causing patients to discontinue their treatment [16, 36, 42].”
Gémes, K., Taipale, H. T., Björkenstam, E., Rahman, S. G., Gustafsson, K., Tanskanen, A. J., Ekselius, L., Mittendorfer‐Rutz, E., & Helgesson, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1152286 · Cited by 7
“These medications have been used as a treatment for ADHD internationally (38), and except for clonidine, all are registered as treatment options for ADHD in Sweden.”
BackgroundIntegrating single-channel EEG neurofeedback into video game-based digital therapeutics for ADHD
Yan, C., Liu, Y., Zhao, J., Bao, M., Zhou, Q., Feng, S., Li, H., Pan, G., Yao, L., & Wang, Y. (2026) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-026-01918-7 · Cited by 6
“…remain a cornerstone of ADHD management, concerns about side effects, limited long-term adherence, and the need for non-invasive alternatives have fueled interest in non-pharmacological interventions, including cognitive training, behavioral therapies, and emerging digital therapeutics [22, 25].”
Schein, J. R., Cloutier, M., Gauthier‐Loiselle, M., Catillon, M., Xu, C., Qu, A., Lee, F., & Childress, A. C. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0089 · Cited by 7
“Furthermore, with the changing treatment landscape in ADHD [23] , physicians and patients would need to be informed about the relative safety and efficacy of newer treatment options relative to existing ones to aid their treatment decisions.”
BackgroundYu, S., Xue, H., Xie, Y., Shao, G., Hao, Y., Fan, L., & Du, W. (2025) · Child and Adolescent Mental Health · doi:10.1111/camh.12744 · Cited by 7
Zhao, F.-Y., Xu, Y., Kennedy, G. A., Conduit, R., Zhang, W., Jiang, T., Xu, P., Ho, J. Y. S., Fu, Q.-Q., & Chow, C. M. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103163 · Cited by 10
Correlational Insights into Attention-Deficit/Hyperactivity Disorder in Lebanon
Assaf, M., Rouphael, M., Nehme, S. B. S., Soufia, M., Alameddine, A., Hallit, S. R., Landry, M., Bitar, T., & Hleihel, W. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21081027 · Cited by 7
“Current pharmacological and non-pharmacological interventions can help address the symptoms of the disorder to alleviate their adverse effects on academic and social functioning [27].”
BackgroundAhumada, J. H., Montalva-Valenzuela, F., Chacón, S. G., Donoso, A. J., Rivas, N. G., Ferrari, G., & Castillo-Paredes, A. (2025) · Psychiatry International · doi:10.3390/psychiatryint6040120 · Cited by 6
Zou, P., Huang, Z., Zong, X., & Zhang, Q. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106436 · Cited by 5
Tripodi, B., Carbone, M. G., Matarese, I., Rizzato, R., Rocca, F. D., Dominicis, F. D., & Callegari, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248848 · Cited by 6
Liu, F., & Yin, X. (2025) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.70195 · Cited by 6
Wiśniewska, K., Wolski, J., Anikiej‐Wiczenbach, P., Żabińska, M., Węgrzyn, G., & Pierzynowska, K. (2025) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-025-02661-5 · Cited by 4
“The ability to perform specific/assigned tasks also improved [132, 133].”
Carmen, C., Agustín, A.-A., Javier, C.-S., & Alberto, R.-A. (2025) · Acta Psychologica · doi:10.1016/j.actpsy.2025.105913 · Cited by 4
Revolucionando nuestros acercamientos al TDAH: nuevas perspectivas desde la Neuroeducación
Parra-Bolaños, N., Tabares, S. B., Gómez, A. E., Pineda, D. A., & Cano, J. A. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v7i2.6013 · Cited by 4
dos Santos, R. M., Nunes, M. K. G., de Souza, L. P., Val, S. N. D. A., Santos, Á. M., da Costa, A. C. V., Lima, L. E. S., Souza, H. D. S., & Teixeira, S. S. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111411 · Cited by 5
Ciocotișan, I.-M., Muntean, D. M., & Vlase, L. (2024) · Metabolites · doi:10.3390/metabo14110588 · Cited by 6
“Similar to ARI, it is used off-label in ADHD, including in pediatric patients [5].”
ADHD, Comorbidities, and Multimodal Treatment
Theodoratou, M., Farmakopoulou, I., & Gkintoni, E. (2023) · Advances in educational technologies and instructional design book series · doi:10.4018/978-1-6684-8203-2.ch013 · Cited by 6
Self-rated costs and benefits of conventional and alternative adult ADHD treatments
Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-79025-7 · Cited by 3
Phatak, M., Nair, B., Soni, U., & Pujari, R. (2025) · Current Drug Metabolism · doi:10.2174/0113892002361676250325082424 · Cited by 3
Mokhtar, H. I., El‐Fadeal, N. M. A., Zayed, M. A., Wahsh, E., Badawy, H. K., Nasr, A., Al‐Emam, A., Nosseir, N., Shehata, S. A., & Zaitone, S. A. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00844-0 · Cited by 3
Ertik, O. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109200 · Cited by 4
Gonda, X., Döme, P., Balogh, L., Baradits, M., & Réthelyi, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.108997 · Cited by 3
Hoseini, R. F., Shalbaf, A., Shoeibi, A., & Pachori, R. B. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.108197 · Cited by 5
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults
Syed, Y. Y. (2025) · CNS Drugs · doi:10.1007/s40263-025-01227-y · Cited by 4
“ADHD is a complex neurodevelopmental condition that often necessitates a multifaceted treatment approach, combining pharmacological and psychological interventions [40].”
Maletic, V., Mattingly, G. W., & Earnest, J. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2327533 · Cited by 2
“Pharmacologic treatment methods for ADHD are traditionally divided into central nervous system (CNS) stimulants and nonstimulants [9,25,27,28].”
BackgroundDezfouli, R. A., Hashemzadeh, S., & Mohammadzadeh, A. S. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00993-2 · Cited by 4
“Management strategies for ADHD are divided into pharmacological and non-pharmacological methods [8, 9], with behavioral therapy being one of the most effective non-pharmacological strategies [10, 11].”
Hazan‐Liran, B., & Walter, O. (2025) · European Journal of Special Needs Education · doi:10.1080/08856257.2025.2549574 · Cited by 2
“…students who seek or are recommended for pharmacological interventions might be experiencing more pronounced psychological or functional impairments, and these could be associated with lower internal resources, including PsyCap and self-esteem (Nazarova et al. 2022, Orth, Erol, and Luciano 2018).”
Hoy, B.-A., Bi, M., Lam, M., Abdalmalak, A., & Fenesi, B. (2025) · Brain Sciences · doi:10.3390/brainsci15101107 · Cited by 2
“The current frontline treatment recommended to children with ADHD is pharma-cotherapy, specifically the use of psychostimulants [1].”
Mahin, A., Joseph, B. B., Sunaina, F., Rasana, F., & Raju, R. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1860515 · Cited by 2
Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)
Wilanowska, W., Gregułą, A., Stachyrak, K., Mika, D., Kłos, A., Turek, K., Lambach, M., Pawlicki, M., Mazurek, A., & Mazur, B. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.58.006 · Cited by 2
Pitt-Francis, A., Stevens, A. R., Ahmed, Z., & Pietro, V. D. (2024) · Trauma Care · doi:10.3390/traumacare5010001 · Cited by 4
“Non-pharmacological ADHD treatment consists of psychological intervention, such as cognitive behavioural therapy (CBT), alongside lifestyle advice [10].”
Tunca, Ç., Güllü, H., Demirtaş, S., Kalkan, K., Tunca, R. D., Efe, A., İbiş, A. N. Ö., Taş, A., Özkan, M. T., Tanık, V. O., et al. (2025) · Journal of Attention Disorders · doi:10.1177/10870547241307680 · Cited by 3
Lee, H.-J., Jeong, Y. J., Kim, J., Kim, S., Jo, U., Jun, S. J., Lim, J., Park, J., Lee, M., Kim, D. Y., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3633 · Cited by 2
Purboyekti, S. (2025) · Journal of Health Innovation and Environmental Education. · doi:10.37251/jhiee.v2i1.2002 · Cited by 2
Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen
Heiser, P., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_10 · Cited by 1
Omozusi, M. O., & Obebe, O. C. (2024) · Pan-African Journal of Health and Environmental Science · doi:10.56893/ajhes2024v03i01.09 · Cited by 2
Dilweg, M. A., Mocking, T. A. M., Maragkoudakis, P., van Westen, G. J. P., Heitman, L. H., IJzerman, A. P., Jespers, W., & van der Es, D. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00521j · Cited by 1
Pandya, S. P. (2024) · Child & Family Behavior Therapy · doi:10.1080/07317107.2024.2429767 · Cited by 1
“Medication is one of the most effective treatments for ADHD, however, it is not effective for all children, leads to side effects for some, and hence is not medically recommended for some, which highlights the need for alternatives (Nazarova et al., 2022).”
TRATAMENTO MEDICAMENTOSO PARA TDAH EM ADULTOS
Rocha, P. A., Soares, A. B. F., Souza, C. N. D., & Soares, M. F. N. (2025) · LUMEN ET VIRTUS · doi:10.56238/levv16n49-022 · Cited by 1
Leme, M. I. D. M., Pinto, C. G. R., & Santos, A. C. D. C. P. (2025) · Research Society and Development · doi:10.33448/rsd-v14i6.48977 · Cited by 1
Chojnacka, B., Ożga, A., Wątor, J., Woźniacka, A., Krzeszowiak, J., Boba, B., Pulanecki, T., Podolska, A., Bryksy, S., & Kolano, P. (2025) · Quality in Sport · doi:10.12775/qs.2025.43.61248 · Cited by 1
“Non-pharmacological interventions have been extensively researched and comprise three principal modalities: psychological methods, complementary interventions and assistive devices [6,7].”
Updates on ADHD in Children and Adolescents: Approach to Diagnosis and Management
Kamal, M., & Mohamed, K. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010652 · Cited by 1
Dahlberg, M., Vessonen, T., Finell, J., Söderberg, P., Aunio, P., Vanhala, A., & Korhonen, J. (2025) · Mental health and physical activity · doi:10.1016/j.mhpa.2025.100725 · Cited by 1
Cognitive Benefits and Challenges of Gaming
Zadey, S., Kelleher, B., & Vasa, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00325-6_11 · Cited by 1
Nutrition for Youth Athletes with ADHD: What We Know and Practical Applications
Becker, T. B., & Gibbs, R. L. (2026) · Nutrients · doi:10.3390/nu18020282 · Cited by 1
“Stimulant medications for ADHD include norepinephrine and dopamine reuptake inhibitors (e.g., methylphenidate), selective noradrenaline reuptake inhibitors (e.g., atomoxetine), and alpha2 adrenergic receptor agonists (e.g., guanfacin) [49].”
Awaji, H., Alharbi, R. A., Mokli, M. B., Balawi, G. M., Alzahrani, Y. S., Khan, A. R., Bima, T. A., Atwie, M. G., Alatwai, A. O., Alatawi, S. A., et al. (2026) · Cureus · doi:10.7759/cureus.102453 · Cited by 2
“However, despite the diverse nature of these interventions [9], a direct comparison between them in terms of effectiveness for the treatment of childhood ADHD is not available.”
Yuan, B., Ao, B., Ali, S., Cai, Q., Chen, Y., & Huang, Y. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341076 · Cited by 1
Soares-Couto, P., Sá, S. I., Costa, V. M., Dias-Carvalho, A., Ferreira, M., Carvalho, F. D., Meisel, A., & Capela, J. P. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04712-y · Cited by 1
Designing with Embodied Metaphors in XR for ADHD
Tazike, M. (2026) · International Conference on Tangible, Embedded, and Embodied Interaction (TEI) · doi:10.1145/3731459.3779041 · Cited by 1
Kim, S.-C., Lee, H., & Lee, S. (2026) · Digital Health · doi:10.1177/20552076261431850 · Cited by 1
“32,33 Therefore, the aim of this pilot study was to explore, via baseline-adjusted comparisons with an active control, the effects of a game-based digital content design explicitly aligned with the core therapeutic targets for children with ADHD (self-regulation and impulse control) on clinical…”
Liu, X., Huang, X., & Song, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1793084 · Cited by 1
“…clinical safety, regulatory restrictions (internal use prohibited in many regions), and the underlying mechanism of PA-induced cytotoxicity). while comparing S. officinale derivatives to conventional treatments to establish relative advantages (Nazarova et al., 2022; Susilawati et al., 2023).”
Electronic media use, sleep behavior, and internalizing problems in adolescent with ADHD
Wiepking, J., Horton, D., & Langlais, M. R. (2026) · Academia Mental Health and Well-Being · doi:10.20935/mhealthwellb8379 · Cited by 1
Uso de Bupropiona para Tratamento do Transtorno de Déficit de Atenção/Hiperatividade (TDAH)
Procópio, J. V. V., Baltazar, B. T., Fidelis, G. P., Gomes, F. W. C., Lacerda, M. V. L. B., Gomes, C. H. F. D. M., Moreira, A. F. C. M., Feitosa, A. D. N. A., Abreu, H. M. B. F., & Neto, M. C. D. B. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e13173.2023 · Cited by 2
Emerging Therapies for Attention-Deficit/Hyperactivity Disorder
Newcorn, J. H. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.muladhd3048sho · Cited by 2
Ali, L., Elsayed, M., & Tawab, A. M. A. (2024) · Egyptian Journal of Health Care · doi:10.21608/ejhc.2024.354404 · Cited by 3
“Sensory and motor complementary treatment is arranged as a Mind-body intervention according to Nazarova, Sokolov, Chubarev, Tarasov & Schiöth (2022).”
MethodAzlan, H. A., Overton, P. G., & Dommett, E. J. (2024) · Advances in Neurodevelopmental Disorders · doi:10.1007/s41252-024-00409-x · Cited by 1
“As concern continues to rise about the use of medication and more psychosocial interventions are being tested in clinical trials (Nazarova et al., 2022) to address gaps in the research about their effectiveness (Goode et al., 2018), it is important to understand what determines a pro-psychosocial…”
Assessing barriers to meditation in patients with substance use disorder
Champagne‐Langabeer, T., Cohen, A. S., Lopez, A., Bakos‐Block, C., Campbell, A., Gopal, B., Cárdenas-Turanzas, M., Poudel, A., Ratcliff, C. G., Malik, A., et al. (2025) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2025.101957 · Cited by 1
Shaikh, M. F., Higley, C., Campanile, C., Francis, B., Panja, E., Santacaterina, S., Pratesi, G., & Piaggio, D. (2024) · doi:10.2196/preprints.64627 · Cited by 1
Cunha, M. P. C. P. D., Lopes, L. R., Amaral, B. A. B., Faccini, A. B. F., Cunha, J. P. C. P. D., Szpilman, A. R. M., Sobral, D. R., & Ribeiro, L. R. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-503
An Objective Assessment of Effect of Stimulants on Attention in Individuals With ADHD
Elliott, G. R., Diner, A., & Sitbon, E. (2024) · Journal of Attention Disorders · doi:10.1177/10870547231215285 · Cited by 2
“Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent condition that can affect individuals of all ages (Alotaibi et al., 2023; Ayano et al., 2023; Nazarova et al., 2022; Polanczyk et al., 2014; Ramsay, 2017; Zhang et al., 2023).”
BackgroundWu, C., Wu, D., Yu, F., & Song, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4249425/v1 · Cited by 3
Atoliya, K., & Khatri, I. (2024) · International Journal of Homoeopathic Sciences · doi:10.33545/26164485.2024.v8.i3c.1207
“These medications, while effective in symptom management, can cause side effects such as insomnia, appetite suppression, and cardiovascular issues [7] .”
Yegencik, B., Deniz, E., & Bell, B. T. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/vb42z
Baktashian, A., Shahriari, M., & Ghasemi, M. (2024) · KMAN Counseling and Psychology Nexus · doi:10.61838/kman.psynexus.2.1.21
Gao, Y., Cao, X., Su, X.-Y., Wu, L., Zhou, P., & Li, T. (2025) · Thermal Science and Engineering Progress · doi:10.1016/j.tsep.2025.103309
RetractedWannapaschaiyong, P. (2025) · Asian Journal of Human Services · doi:10.14391/ajhs.28.289
Toole, K. P., & Frank, C. (2025) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000085
“62 These nonstimulants are useful in patients who cannot tolerate the adverse effects of stimulants, are at high risk for stimulant misuse, or have contraindications to stimulant use, such as having a congenital heart defect.”
Lai, Y. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.24228
Chikkanna, U., Kommu, J. V. S., Shivakumar, V., Holla, B., Mundada, P. S., Gokulakrishnan, K., Debnath, M., Rajendra, K. M., Roopesh, B., Sahoo, S., et al. (2025) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000367
Tratamento medicamentoso recomendado para adultos com TDAH
Rocha, P. A., Soares, A. B. F., de Souza, C. N., & Soares, M. F. N. (2025) · Editora Científica Digital eBooks · doi:10.37885/250619470
TDAH em adultos: do diagnóstico ao manejo
Rocha, P. A., Alencar, R. D. C., & Martins, A. L. D. A. (2025) · Editora Científica Digital eBooks · doi:10.37885/978-65-5360-971-6
Hamadi, H. Y., Thomas, R. M., Xie, Z., Patterson, K. B., & Spaulding, A. (2025) · Journal of Drug Issues · doi:10.1177/00220426251364375
METILFENIDATO SUKELIAMAS NEPAGEIDAUJAMAS POVEIKIS GYDANT AKTYVUMO IR DĖMESIO SUTRIKIMĄ
Aliukonytė, O., & Bukelskis, L. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.249
Metadata
- Authors
- Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B.
- Affiliations
- Uppsala University (SE)
- Corresponding author
- Schiöth, Helgi B.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-17
- Volume
- 13
- Pages
- 1066988-1066988
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC9713849
- OpenAlex
- W4309604196
- Cited by
- 111
- References
- 96
- Citations by year
- 2026: 24 · 2025: 51 · 2024: 24 · 2023: 12
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Brain Research Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- attention deficit hyperactivity disorder, ADHD treatment, pharmacotherapy, non-pharmacological treatment, psychostimulants, methylphenidate, atomoxetine, guanfacine, clonidine, noradrenergic reuptake inhibitors, antidepressants, atypical antipsychotics, behavioral interventions, social skills training, meditation, hypnotherapy, sleep interventions, physical activity interventions, clinical trial trends, therapeutic target, complementary and alternative medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.